drugset / Trial / NCT03167177
QUILT-3.046: NANT Melanoma Vaccine: Combination Immunotherapy in Subjects With Melanoma Who Have Progressed On or After Chemotherapy and PD-1/PD-L1 Therapy
NaSingle-groupOpen-labelTreatment
Summary
This is a phase 1b/2 study to evaluate the safety and efficacy of metronomic combination therapy in subjects with melanoma who have progressed on or after chemotherapy and anti-PD-1/PD-L1 therapy.
Timeline
- Start
- 2017-12
- Primary completion
- 2019-01
- Completion
- 2021-12-28
Outcome
Outcome not reported
Stopped: “Trial not initiated”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Background | Avelumab | Monoclonal antibody | — | — |
| Background | Bevacizumab | Monoclonal antibody | — | — |
| Background | Capecitabine | Small molecule | — | — |
| Background | Cisplatin | Other / unclassified | — | — |
| Background | Cyclophosphamide | Other / unclassified | — | — |
| Background | ETBX-011 | Vaccine | — | — |
| Background | ETBX-051 | Vaccine | — | — |
| Background | ETBX-061 | Vaccine | — | — |
| Background | GI-6207 | Vaccine | — | — |
| Background | GI-6301 | Vaccine | — | — |
| Background | Leucovorin | Small molecule | — | — |
| Background | Lovaza | Other / unclassified | — | — |
| Background | N-803 | Protein / enzyme biologic | — | — |
| Background | Nab-paclitaxel | Small molecule | — | — |
| Background | Nivolumab | Monoclonal antibody | — | — |
| Background | fluorouracil | Small molecule | — | — |
| Background | haNK | Cell therapy | — | — |